Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus iodine-125 seed implantation for locally advanced or metastatic differentiated thyroid cancer
ChiCTR2200063945Phase 3Not yet recruiting
- Sponsor
- Hebei General Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anlotinib in well-differentiated thyroid cancer (WDTC) (3 arms), sponsored by Hebei General Hospital. Primary endpoint: Objective response rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2200063945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063945.